Home › Research › Prevention and risk
Herpes Zoster Vaccination and Dementia Occurrence (Australian natural experiment)
Pomirchy M, Bommer C, Pradella F, Michalik F, Peters R, Geldsetzer P. JAMA, 2025-06-17
Topic: Risk, prevention and care in population studies
Plain-language summary
Importance Recent evidence from a quasi-experiment in Wales showed that herpes zoster (HZ) vaccination appears to prevent or delay dementia. Exploiting a similar quasi-experiment in Australia, this study investigated the effect of HZ vaccination on dementia occurrence in a different population and health system setting. Objective To determine the effect of HZ vaccination on the probability of receiving a new diagnosis of dementia. Design, setting, and participants In Australia, starting November 1, 2016, live attenuated HZ vaccination was provided free to individuals aged 70 to 79 years through primary care clinicians. Thus, individuals whose 80th birthday was just a few weeks before November 1, 2016, never became eligible, whereas those whose 80th birthday was just a few weeks later were eligible. The key strength of this quasi-experiment is that one would not expect that these comparison groups who differ in age only minutely would, on average, differ in any health characteristics and behaviors. Primary health care records were analyzed with week-of-birth information from 65 general practices across Australia, using a regression discontinuity design. Exposure Eligibility for HZ vaccination based on date of birth. Main outcome New diagnoses of dementia as recorded in primary care electronic health record data. Results In this sample of 101 219 patients, 52.7% were women and mean age was 62.6 years (SD, 9.3 years) as of November 1, 2016. Individuals born just before vs just after the date-of-birth eligibility threshold (November 2, 1936) for HZ vaccination were well balanced in their past preventive health services uptake and past chronic disease diagnoses. There was an abrupt increase of 16.4 percentage points (95% CI, 13.2-19.5; P Conclusions and relevance By taking advantage of a quasi-experiment and corroborating findings from Wales in a different population, this study provides evidence of the potential benefits of HZ vaccination for dementia that is more likely to be causal than that of more commonly conducted associational studies.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 101,219 participants. This Australian natural experiment examined whether herpes zoster vaccination affects the chance of a new dementia diagnosis, using eligibility based on date of birth. Its stated limit: Estimates the effect of eligibility rather than vaccination itself (only a minority took it up); primary care records may miss diagnoses; the live attenuated vaccine studied has since been replaced by the recombinant vaccine in many countries.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Pomirchy, M., Bommer, C., Pradella, F., Michalik, F., Peters, R., & Geldsetzer, P. (2025). Herpes Zoster Vaccination and Dementia Occurrence (Australian natural experiment). JAMA. https://doi.org/10.1001/jama.2025.5013
Vancouver
Pomirchy M, Bommer C, Pradella F, Michalik F, Peters R, Geldsetzer P. Herpes Zoster Vaccination and Dementia Occurrence (Australian natural experiment). JAMA. 2025. doi:10.1001/jama.2025.5013. PMID: 40267506.
BibTeX
@article{pomirchy2025-40267506,
author = {Pomirchy, M. and Bommer, C. and Pradella, F. and Michalik, F. and Peters, R. and Geldsetzer, P.},
title = {{Herpes Zoster Vaccination and Dementia Occurrence (Australian natural experiment)}},
journal = {JAMA},
year = {2025},
doi = {10.1001/jama.2025.5013},
pmid = {40267506},
url = {https://doi.org/10.1001/jama.2025.5013}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Importance Recent evidence from a quasi-experiment in Wales showed that herpes zoster (HZ) vaccination appears to prevent or delay dementia.
- Results In this sample of 101 219 patients, 52.7% were women and mean age was 62.6 years (SD, 9.3 years) as of November 1, 2016.
Why it matters
This Australian natural experiment examined whether herpes zoster vaccination affects the chance of a new dementia diagnosis, using eligibility based on date of birth. The text provided does not report the study's results, so it is not possible to say whether vaccination affected dementia occurrence.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Study designcohort
- Participants101,219
- Effect size-1.8 percentage points (95% CI -3.3 to -0.4) absolute reduction in new dementia diagnoses over 7.4 years for the vaccine-eligible group
- Evidence strengthModerate
Limitations
Estimates the effect of eligibility rather than vaccination itself (only a minority took it up); primary care records may miss diagnoses; the live attenuated vaccine studied has since been replaced by the recombinant vaccine in many countries.
How this study scored 78/100
Published in a top-tier journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 76 of the 98 points we could judge it on, which is 78 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (JAMA) |
| Journal's citation record | 4 / 4 | JAMA: journal h-index 1,011 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 4 / 4 | 101,219 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 69 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 23.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 6 / 6 | Cited 43.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 3 / 4 | Cited 69 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Pascal Geldsetzer: h-index 48 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Stanford University: institution h-index 2,684 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 9 institution(s) in 4 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40267506) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 76 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 76 of the 98 points we could judge it on is 78 out of 100. |
| Total | 78 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.